Earth-abundant metal (EAM) catalysis can have profound impact in the pharmaceutical industry in terms of sustainability and cost improvements from replacing precious metals like palladium as well as harnessing the differential reactivity of first-row metals that allows for novel transformations to enable more efficient routes to clinical candidates. The strategy for building these capabilities within the process group at Bristol Myers Squibb is described herein, with the general plan of building a reaction screening platform, demonstrating scalability, and increasing mechanistic understanding of the reaction and catalyst activation. The development of catalytic transformations utilizing nickel, cobalt, and iron is described while highlighting the importance of collaboration with internal and external groups to advance EAM catalysis and impact our portfolio. The challenges and benefits of working with first-row transition metals, including metrics for the implementation of EAM catalysis, such as cost, process mass intensity, and commercial availability of catalysts and ligands, are discussed.

中文翻译：

---

合作是提高地球丰富金属催化能力的关键

地球丰富的金属 (EAM) 催化可以在可持续性和成本改善方面对制药行业产生深远的影响，因为它可以取代钯等贵金属，并利用第一排金属的差异反应性，实现新颖的转化，从而为临床候选者提供更有效的途径。本文描述了在百时美施贵宝工艺组内构建这些能力的策略，以及构建反应筛选平台、展示可扩展性以及增加对反应和催化剂活化的机理理解的总体计划。利用镍、钴、描述了铁，同时强调了与内部和外部团体合作的重要性，以推进 EAM 催化并影响我们的投资组合。讨论了使用第一排过渡金属的挑战和好处，包括实施 EAM 催化的指标，例如成本、工艺质量强度以及催化剂和配体的商业可用性。